Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
Would your treatment recommendations change for patients with ESRD or on dialysis?
Related Questions
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?